Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study
Journal of Medical Virology · 2024
DOI: 10.1002/jmv.29642 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Medical Virology, 2024. Verfasst von Cesare Ernesto Maria Gruber und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, Genome, Viral, Hydroxylamines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Commission, Ministero della Salute, Ministero della Salute: Ricerca Corrente-linea 1, and 5 per Mille-Progetto.
Abstract (Originalsprache)
Molnupiravir, an oral direct‐acting antiviral effective in vitro against SARS‐CoV‐2, has been largely employed during the COVID‐19 pandemic, since December 2021. After marketing and widespread usage, a progressive increase in SARS‐CoV‐2 lineages characterized by a higher transition/transversion ratio, a characteristic signature of molnupiravir action, appeared in the Global Initiative on Sharing All Influenza Data (GISAID) and International Nucleotide Sequence Database Collaboration (INSDC) databases. Here, we assessed the drug effects by SARS‐CoV‐2 whole‐genome sequencing on 38 molnupiravir‐treated persistently positive COVID‐19 outpatients tested before and after treatment. Seventeen tixagevimab/cilgavimab‐treated outpatients served as controls. Mutational analyses confirmed that SARS‐CoV‐2 exhibits an increased transition/transversion ratio seven days after initiation of molnupiravir. Moreover we observed an increased G‐>A ratio compared to controls, which was not related to apolipoprotein B mRNAediting enzyme, catalytic polypeptide‐like (APOBEC) activity. In addition, we demonstrated for the first time an increased diversity and complexity of the viral quasispecies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Virology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
- Department of Biology, University of Rome Tor Vergata, Rome, Italy.
- Clinical and Research Infectious Diseases Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
- Laboratory of Microbiology, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
- North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.
- Scientific Direction, National Institute for Infectious Diseases "L. Spallanzani"-IRCCS, Rome, Italy.
ORCID-Profile: Cesare Ernesto Maria Gruber, Valentina Mazzotta, Martina Rueca, Daniele Focosi
Förderung
- European Commission
- Ministero della Salute
- Ministero della Salute: Ricerca Corrente-linea 1, and 5 per Mille-Progetto
- European Commission: HORIZON-INFRA-2021-EMERGENCY-01
Zitieren
APA
Gruber, C. E. M., Tucci, F. G., Giombini, E., Mazzotta, V., Spezia, P. G., Rueca, M., Mastrorosa, I., Fabeni, L., Berno, G., Butera, O., Rosati, S., Specchiarello, E., Carletti, F., Focosi, D., Nicastri, E., Girardi, E., Antinori, A., & Maggi, F. (2024). Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study. Journal of Medical Virology. https://doi.org/10.1002/jmv.29642
Vancouver
Gruber CEM, Tucci FG, Giombini E, Mazzotta V, Spezia PG, Rueca M, et al. Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study. Journal of Medical Virology. 2024. doi:10.1002/jmv.29642
BibTeX
@article{Gruber2024,
author = {Gruber, Cesare Ernesto Maria and Tucci, Fabio Giovanni and Giombini, Emanuela and Mazzotta, Valentina and Spezia, Pietro Giorgio and Rueca, Martina and Mastrorosa, Ilaria and Fabeni, Lavinia and Berno, Giulia and Butera, Ornella and Rosati, Silvia and Specchiarello, Eliana and Carletti, Fabrizio and Focosi, Daniele and Nicastri, Emanuele and Girardi, Enrico and Antinori, Andrea and Maggi, Fabrizio},
title = {Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study},
journal = {Journal of Medical Virology},
year = {2024},
doi = {10.1002/jmv.29642}
}
EUVIMED